2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials
Lebwohl M, Merola J, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb A. Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials. Journal Of The American Academy Of Dermatology 2024, 91: 281-289. PMID: 38588819, DOI: 10.1016/j.jaad.2024.03.041.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsAdverse eventsModerate to severe plaque psoriasisIncidence of transaminase elevationsLiver parametersMarkers of liver fibrosisAlanine aminotransferaseHepatic adverse eventsSevere plaque psoriasisLiver function abnormalitiesChronic alcohol consumptionControl study periodAspartate aminotransferaseStudy periodAPRI scorePlaque psoriasisTransaminase elevationFibrosis riskHepatic eventsFIB-4Hepatic dysfunctionLaboratory elevationsClinical markersFunctional abnormalitiesLiver fibrosis
2023
Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program
Lebwohl M, Egeberg A, Linaberry M, Hoyt K, Banerjee S, Kisa R, Strober B. Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program. SKIN The Journal Of Cutaneous Medicine 2023, 7: s116. DOI: 10.25251/skin.7.supp.116.Peer-Reviewed Original ResearchSevere plaque psoriasisAlanine aminotransferasePlaque psoriasisConcomitant medicationsWeeks 0Week 16Multiple laboratory parametersCommon Terminology CriteriaMean levelsTreatment of adultsWeeks of treatmentPatient-level dataOral placeboTerminology CriteriaAST elevationLiver transaminasesAminotransferase levelsCTCAE gradeLiver dysfunctionSystemic therapyLaboratory parametersAST levelsTreatment armsLiver conditionsSeverity grade